NVTA:NYE-Invitae Corporation

EQUITY | Medical Diagnostics & Research | New York Stock Exchange

Last Closing

USD 23.55

Change

0.00 (0.00)%

Market Cap

USD 0.23B

Volume

3.39M

Analyst Target

USD 23.79
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Invitae Corp is a genetic information company engaged in genetic diagnostics for hereditary disorders. It provides testing for multiple genes including hereditary cancer, neurological disorders, cardiovascular disorders and other hereditary conditions.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-03-24 )

Largest Industry Peers for Medical Diagnostics & Research

ETFs Containing NVTA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Diagnostics & Research) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 112.93% 100% F 100% F
Dividend Return N/A N/A N/A N/A F
Total Return 112.93% 100% F 100% F
Trailing 12 Months  
Capital Gain 235.47% 100% F 100% F
Dividend Return N/A N/A N/A N/A F
Total Return 235.47% 100% F 100% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Average Annual (5 Year Horizon)  
Capital Gain 5.71% 12% F 70% C-
Dividend Return 5.71% 12% F 55% F
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 40.76% 12% F 10% F
Risk Adjusted Return 14.02% 12% F 32% F
Market Capitalization 0.23B 24% F 67% D+

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Diagnostics & Research) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -12.02 94% 86%
Price/Book Ratio 9.85 12% 6%
Price / Cash Flow Ratio -3.98 94% 95%
Price/Free Cash Flow Ratio -15.19 100% 89%
Management Effectiveness  
Return on Equity -88.93% 6% 2%
Return on Invested Capital -59.73% 6% 1%
Return on Assets -50.99% 6% 0%
Debt to Equity Ratio 48.50% 59% 63%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector